SCHEMBL25268625

SCHEMBL25268625

c1cc(CCc2ccc3ncnc(N4CC5(CCNCC5)C4)c3c2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 6/20 0.46
▸ HTT P42858 2/20 0.43
▸ CYP3A4 P08684 12/20 0.42
▸ CYP1A2 P05177 11/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ HPGD P15428 5/20 0.40
▸ CYP2C19 P33261 8/20 0.40
▸ ALDH1A1 P00352 7/20 0.40
▸ TSHR P16473 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HSD17B10 Q99714 6/20 0.39
▸ CLK4 Q9HAZ1 7/20 0.38
▸ USP2 O75604 4/20 0.38
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31501707 1.00 CYP2D6 (0.46) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL31501711 0.90 HTT (0.44) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL25227852 0.90 HTT (0.44) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL31501706 0.89 HTT (0.43) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL31027439 0.88 CYP1A2 (0.51) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL25276551 0.88 CYP1A2 (0.51) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL31501681 0.88 CYP1A2 (0.51) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL31501696 0.86 CYP3A4 (0.48) CYP2D6HTTCYP3A4CYP1A2CYP2C19
SCHEMBL31501710 0.84 HTT (0.41) CYP2D6HTTCYP3A4CYP1A2KDM4E
SCHEMBL25234444 0.83 PDGFRB (0.41) CYP2D6CYP3A4CYP1A2HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
EP-4444313-A1 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
CN-118647378-A Inhibitors of Mei Nen protein interaction with MLL 巴拉疗法公司 2024-09-13 — — CN disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
WO-2023107696-A2 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 CYP2D6 4232/4885HTT 3578/4885CYP3A4 4263/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 CYP2D6 4232/4885HTT 3578/4885CYP3A4 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback